Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study
Cancer · 2025-01 · 131 (1)
DOI: 10.1002/cncr.35476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 10.07.2024. Verfasst von Yating Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology, Ascension Providence Hospital, Southfield, Michigan, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, SEER Program. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
In 2015, the US Food and Drug Administration approved nivolumab as the first immunotherapy for patients with advanced non–small cell lung cancer (NSCLC). However, population‐based survival benefit studies after the introduction of immunotherapy in lung cancer are lacking. This study examined overall survival (OS) and cancer‐specific survival in patients with NSCLC in the pre immunotherapy and immunotherapy eras.
Methods
This study used the Surveillance, Epidemiology, and End Results database, which spanned 17 registries from 2000 to 2020. Two cohorts were delineated: preimmunotherapy (2010–2014) and immunotherapy (2015–2020), which coincided with nivolumab’s approval.
Results
This study included 191,802 patients, 90,807 in the preimmunotherapy era and 100,995 in the immunotherapy era. OS was significantly higher in the immunotherapy era, as shown by Kaplan–Meier curves (1‐year OS, 40.1% vs. 33.5%; 3‐year OS, 17.8% vs. 11.7%; 5‐year OS, 10.7% vs. 6.8%; median OS, 8 vs. 7 months; p < .001 by log‐rank test). Similarly, cancer‐specific survival improved in the immunotherapy era (1‐year survival, 44.0% vs. 36.8%; 3‐year survival, 21.7% vs. 14.4%; 5‐year survival, 14.3% vs. 9.0%; median OS, 10 vs. 8 months; p < .001 by log‐rank test). Survival rates were significantly better in the immunotherapy era, as confirmed by multivariate analysis with a Cox proportional hazards model after adjusting for age, sex, race, income, and geographical area (adjusted hazard ratio, 0.830; 95% CI, 0.821–0.840; p < .001).
Conclusions
In summary, the survival rate of patients with metastatic NSCLC has improved since the introduction of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Oncology, Ascension Providence Hospital, Southfield, Michigan, USA.
- Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
- Internal Medicine, Northernlight Eastern Maine Medical Center, Bangor, Maine, USA.
- Internal Medicine, Logan Regional Medical Center, Logan, West Virginia, USA.
- Interventional Radiology, University of Chicago Medical Center, Chicago, Illinois, USA.
ORCID-Profile: Yating Wang, Quynh Nguyen, Qian Yu, Dipesh Uprety
Zitieren
APA
Wang, Y., Kondrat, K., Adhikari, J., Nguyen, Q., Yu, Q., & Uprety, D. (2025). Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study. Cancer, 131(1). https://doi.org/10.1002/cncr.35476
Vancouver
Wang Y, Kondrat K, Adhikari J, Nguyen Q, Yu Q, Uprety D. Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study. Cancer. 2025;131(1). doi:10.1002/cncr.35476
BibTeX
@article{Wang2025,
author = {Wang, Yating and Kondrat, Kyle and Adhikari, Janak and Nguyen, Quynh and Yu, Qian and Uprety, Dipesh},
title = {Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study},
journal = {Cancer},
year = {2025},
volume = {131},
number = {1},
doi = {10.1002/cncr.35476}
}
EUVIMED